Novartis announces global partnership with Amgen
Novartis announced a global collaboration with Amgen to commercialize and develop pioneering neuroscience treatments. The companies will partner in the development and commercialization of a BACE inhibitor program in Alzheimer's Disease. Novartis' oral therapy CNP520 will be the lead molecule. September 01, 2015